Guideline for the diagnosis and management of myelofibrosis.

Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).

JAK2 inhibitors and their impact in myeloproliferative neoplasms.

RNAi screening of the kinome with cytarabine in leukemias.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

Ruxolitinib.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.